MARC record from Internet Archive

LEADER: 10796cam 2200793 i 4500
001 ocn869226782
003 OCoLC
005 20210721232305.0
008 140127s2013 sz ab b i100 0 eng c
040 $aTPHM$beng$erda$cTPH$dUKMGB$dNUI$dYDXCP$dHMS$dIUL$dBTCTA$dUMC$dINU$dOCLCQ$dNZWMM$dOCLCA$dNJR$dCHVBK$dOCLCO$dCEF$dFQG$dOCLCO$dCOBAS$dOCLCO$dOCLCA$dQE2$dSFB$dOCL$dOCLCO
016 7 $a016611529$2Uk
019 $a871335310$a1179451448
020 $a9789241209847$q(pbk.)
020 $a9241209844$q(pbk.)
020 $a9789240691728
020 $a9240691723
035 $a(OCoLC)869226782$z(OCoLC)871335310$z(OCoLC)1179451448
042 $apcc
050 14 $aRA8$b.A25 no. 984
050 14 $aRC186.T82$bC667 2013
055 5 $aRC*
060 14 $aWC 705
082 04 $a616.9363
084 $a44.75$2bcl
245 00 $aControl and surveillance of human African trypanosomiasis :$breport of a WHO Expert Committee.
246 3 $aControl & surveillance of human African trypanosomiasis
264 1 $aGeneva :$bWorld Health Organization,$c2013.
300 $ax, 237 pages :$billustrations, maps ;$c22 cm.
336 $atext$btxt$2rdacontent
337 $aunmediated$bn$2rdamedia
338 $avolume$bnc$2rdacarrier
490 1 $aWHO technical report series,$x0512-3054 ;$v984
500 $a"WHO Expert Committee on the Control and Surveillance of Human African Trypanosomiasis, Geneva, 22-26 April 2013"--Page ix.
504 $aIncludes bibliographical references.
505 00 $gMachine generated contents note:$g2.1.$tTwo diseases, two parasites, two epidemiological patterns --$g2.2.$tTransmission cycle --$g2.2.1.$tGambiense human African trypanosomiasis --$g2.2.2.$tRhodesiense human African trypanosomiasis --$g2.3.$tReservoirs of infection --$g2.3.1.$tGambiense human African trypanosomiasis --$g2.3.2.$tRhodesiense human African trypanosomiasis --$g2.4.$tRisk factors for infection --$g2.4.1.$tGambiense human African trypanosomiasis --$g2.4.2.$tRhodesiense human African trypanosomiasis --$g2.5.$tTrends in numbers of cases reported --$g2.5.1.$tGambiense human African trypanosomiasis --$g2.5.2.$tRhodesiense human African trypanosomiasis --$g2.6.$tGeographical distribution and population at risk --$g2.7.$tGlobal environmental change --$g2.8.$tReferences --$g3.1.$tTaxonomy of human infectious African trypanosomes --$g3.2.$tMorphology and cell structure --$g3.3.$tLife-cycle --$g3.4.$tThe Trypanosoma brucei genome --$g3.5.$tImmune evasion --$g3.6.$tBiochemistry and modes of drug action.
505 00 $g3.7.$tDrug resistance --$g3.8.$tReferences --$g4.1.$tClassification --$g4.1.1.$tSubgenus Nemorhina --$g4.1.2.$tSubgenus Glossina s. str. --$g4.1.3.$tSubgenus Austenina --$g4.2.$tReproductive system --$g4.3.$tReproduction --$g4.4.$tLifespan and population dynamics --$g4.5.$tDiet --$g4.6.$tGeographical distribution of the main vector species --$g4.6.1.$tVector species of the Nemorhina subgenus --$g4.6.2.$tVector species of the Glossina s. str. subgenus --$g4.6.3.$tVector species of the Austenina subgenus --$g4.7.$tTsetse flies in their natural environment --$g4.7.1.$tMain habitats --$g4.7.2.$tMovements --$g4.7.3.$tLooking for hosts --$g4.7.4.$tFeeding preferences --$g4.7.5.$tActivity cycles --$g4.7.6.$tDispersal --$g4.7.7.$tResting places --$g4.8.$tPopulation genetics and geometric morphometrics --$g4.9.$tGenomics of tsetse flies --$g4.10.$tTsetse flies as cyclical vectors --$g4.11.$tVector control strategies --$g4.11.1.$tControl --$g4.11.2.$tEradication --$g4.11.3.$tPreliminary surveys --$g4.12.$tTsetse fly control methods --$g4.12.1.$tBush clearing --$g4.12.2.$tElimination of wild animal hosts.
505 00 $g4.12.3.$tBiological control of tsetse flies --$g4.12.4.$tAutonomous control of tsetse flies --$g4.12.5.$tIndigenous tsetse fly control practices --$g4.12.6.$tGround and aerial insecticide spraying --$g4.12.7.$tProtecting zero grazing units by insecticide-impregnated netting --$g4.12.8.$tBait methods --$g4.12.9.$tOlfactory baits (attractants) for tsetse flies --$g4.12.10.$tLive baits --$g4.12.11.$tSterile insect technique --$g4.13.$tNew developments and outlook --$g4.14.$tReferences --$g5.1.$tGambiense human African trypanosomiasis: clinical signs and symptoms --$g5.1.1.$tLymphadenopathy --$g5.1.2.$tFever --$g5.1.3.$tHeadache --$g5.1.4.$tPruritus --$g5.1.5.$tMusculoskeletal pain, hepatomegaly and splenomegaly --$g5.1.6.$tCardiac involvement --$g5.1.7.$tGastrointestinal symptoms --$g5.1.8.$tOedema --$g5.1.9.$tSleep disorder --$g5.1.10.$tNeuropsychiatric symptoms and signs --$g5.1.11.$tEndocrine disorders --$g5.2.$tRhodesiense human African trypanosomiasis: clinical signs and symptoms --$g5.3.$tSpecific groups --$g5.3.1.$tChildren --$g5.3.2.$tHIV-coinfected patients.
505 00 $g5.3.3.$tHuman African trypanosomiasis in nonendemic countries --$g5.4.$tSequelae --$g5.5.$tReferences --$g6.1.$tDiagnosis of gambiense human African trypanosomiasis --$g6.1.1.$tAntibody detection --$g6.1.2.$tParasite detection --$g6.1.3.$tMolecular detection --$g6.2.$tDiagnosis of rhodesiense human African trypanosomiasis --$g6.2.1.$tAntibody detection --$g6.2.2.$tParasite detection --$g6.2.3.$tMolecular detection --$g6.3.$tDisease stage determination --$g6.3.1.$tWhite blood cell count --$g6.3.2.$tParasite detection in cerebrospinal fluid --$g6.3.3.$tOther staging markers --$g6.3.4.$tMolecular tests --$g6.4.$tTreatment outcome assessment --$g6.5.$tQuality control of diagnostic testing --$g6.6.$tNew developments and outlook --$g6.7.$tReferences --$g7.1.$tPharmacology of drugs for treatment of first-stage human African trypanosomiasis --$g7.1.1.$tPentamidine --$g7.1.2.$tSuramin --$g7.2.$tPharmacology of drugs for treatment of second-stage human African trypanosomiasis --$g7.2.1.$tMelarsoprol --$g7.2.2.$tEflornithine --$g7.2.3.$tNifurtimox.
505 00 $g7.3.$tFirst-line treatment --$g7.3.1.$tFirst-stage gambiense human African trypanosomiasis: pentamidine --$g7.3.2.$tFirst-stage rhodesiense human African trypanosomiasis: suramin --$g7.3.3.$tSecond-stage gambiense human African trypanosomiasis: nifurtimox-eflornithine combination therapy --$g7.3.4.$tSecond-stage rhodesiense human African trypanosomiasis: melarsoprol --$g7.4.$tAlternative treatments for second-stage gambiense human African trypanosomiasis --$g7.4.1.$tEflornithine monotherapy --$g7.4.2.$tMelarsoprol --$g7.5.$tTreatment in pregnancy --$g7.6.$tNew developments and outlook --$g7.6.1.$tPreclinical and clinical developments --$g7.6.2.$tResearch on other compounds --$g7.7.$tReferences --$g8.1.$tDetection of cases of gambiense human African trypanosomiasis --$g8.1.1.$tActive case detection --$g8.1.2.$tPassive case detection --$g8.1.3.$tManagement of parasitologically unconfirmed seropositive cases --$g8.2.$tDetection of cases of rhodesiense human African trypanosomiasis --$g8.2.1.$tActive case detection --$g8.2.2.$tPassive case detection.
505 00 $g8.3.$tControl of animal reservoirs --$g8.3.1.$tControl in the domestic livestock reservoir --$g8.3.2.$tControl in the wildlife reservoir --$g8.4.$tVector control --$g8.4.1.$tMethods --$g8.4.2.$tTraps and screens --$g8.4.3.$tInsecticide-treated cattle for control of rhodesiense human African trypanosomiasis --$g8.4.4.$tImplementation of vector control --$g8.5.$tElimination of gambiense human African trypanosomiasis --$g8.5.1.$tRationale --$g8.5.2.$tConcept of elimination, indicators and benchmarks --$g8.5.3.$tStrategies for elimination --$g8.5.4.$tChallenges --$g8.6.$tElimination of rhodesiense human African trypanosomiasis --$g8.7.$tReferences --$tAnnex 1 Wild animal species documented as serving as hosts for Trypanosoma brucei rhodesiense --$tAnnex 2 Distribution of human African trypanosomiasis in West Africa --$tAnnex 3 Distribution of human African trypanosomiasis in Central Africa --$tAnnex 4 Distribution of human African trypanosomiasis in East and south-eastern Africa --$tAnnex 5 Cryostabilization --$tAnnex 6 Trap types used to capture various species of tsetse fly.
505 00 $tAnnex 7 Protocol for storing blood samples on filter paper discs --$tAnnex 8 Storage of blood samples in AS1 buffer --$tAnnex 9 Preparation of guanidine hydrochloride-ethylene diamine tetraacetic acid (EDTA) buffer --$tAnnex 10 Protocol for storage of blood samples in guanidine hydrochloride-ethylene diamine tetraacetic acid (EDTA) buffer --$tAnnex 11 Example of a field algorithm for diagnosis of Trypanosoma brucei gambiense infection --$tAnnex 12 Strategy for the elimination of gambiense human African trypanosomiasis in foci with high or moderate transmission (annual incidence> 1 case per 10 000 inhabitants in previous 5 years) --$tAnnex 13 Strategy for the elimination of gambiense human African trypanosomiasis in foci with low transmission (annual incidence> 1 case per 1 000 000 and <1 case per 10 000 inhabitants in previous 5 years).
520 $a"This report provides information about new diagnostic approaches, new therapeutic regimens and better understanding of the distribution of the disease with high-quality mapping. The roles of human and animal reservoirs and the tsetse fly vectors that transmit the parasites are emphasized. The new information has formed the basis for an integrated strategy with which it is hoped that elimination of gambiense HAT will be achieved. The report also contains recommendations on the approaches that will lead to elimination of the disease"--Back cover.
540 $aCurrent Copyright Fee: GBP17.50$c0.$5Uk
650 0 $aAfrican trypanosomiasis$xPrevention.
650 0 $aAfrican trypanosomiasis$xEpidemiology.
650 12 $aTrypanosomiasis, African$xprevention & control$vCongresses.
650 12 $aTrypanosomiasis, African$xepidemiology$vCongresses.
650 12 $aPopulation Surveillance$xmethods$vCongresses.
650 7 $aAfrican trypanosomiasis$xPrevention.$2fast$0(OCoLC)fst00799913
650 7 $aAfrican trypanosomiasis$xEpidemiology.$2fast$0(OCoLC)fst00799911
650 7 $aAfrican trypanosomiasis.$2fast$0(OCoLC)fst00799907
650 7 $aTrypanosomiase$2gnd
650 7 $aÄtiologie$2gnd
650 17 $aTrypanosomiasis.$2gtt
650 17 $aVerspreiding.$2gtt
650 17 $aBestrijding.$2gtt
653 1 $aAfrican trypanosomiasis
653 1 $aHuman African trypanosomiasis
655 2 $aCongress.
710 2 $aWHO Expert Committee on the Control and Surveillance of Human African Trypanosomiasis.
830 0 $aTechnical report series (World Health Organization) ;$v984.
938 $aBaker and Taylor$bBTCP$nBK0014567522
938 $aYBP Library Services$bYANK$n11671339
029 1 $aAU@$b000052536976
029 1 $aCHVBK$b50781682X
029 1 $aCHBIS$b011132140
029 1 $aUKMGB$b016611529
994 $aZ0$bP4A
948 $hNO HOLDINGS IN P4A - 51 OTHER HOLDINGS